NCT07445022
RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
Recruiting · Phase 4 · Fudan University · registry updated 2026-03-03
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.
Inclusion
- Aged ≥18 years (inclusive), male or female;
- Patients with histologically or cytologically confirmed locally advanced or metastatic melanoma;
- Prior genetic testing results showing positive NRAS mutation;
- Patients who have failed prior anti-PD-1/PD-L1 therapy;
- Able to take oral medications;
- Voluntarily participate and sign the informed consent form, expected to have good compliance, and able to cooperate with the study according to the protocol requirements.
Exclusion
- Currently participating in other clinical trials of drugs;
- Patients who are pregnant or breastfeeding;
- Other conditions deemed unsuitable for targeted therapy after multidisciplinary discussion;
- Other conditions considered inappropriate for inclusion by the investigator, such as familial or social factors that may affect the safety of the subject or the collection of data.